New treatment for managing sickle cell disease using a special type of heparin
Sulfated Non-Anticoagulant Heparin Nanoparticle (VVP728) for Sickle Cell Disease Management
This study is testing a new treatment for sickle cell disease that uses special nanoparticles to help reduce pain and improve daily life for patients, without the bleeding risks that come with some current treatments.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vascular Vision Pharmaceuticals Company NIH-funded |
| Lab location | 1 site (Wynantskill, United States) |
| Project ID | NIH-10883777 on NIH RePORTER |
What this research studies
This research focuses on developing a novel treatment for sickle cell disease (SCD) using sulfated non-anticoagulant heparin nanoparticles. The approach aims to address the limitations of existing therapies by providing a multi-modal treatment that enhances patient outcomes without the risk of bleeding, a common side effect of current low molecular weight heparins. The study will evaluate the safety and efficacy of this new treatment in improving the quality of life for patients suffering from SCD, particularly targeting the painful vaso-occlusive crises that significantly impact their daily lives.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with sickle cell disease, particularly those who experience frequent painful crises and have not responded adequately to existing treatments.
Not a fit: Patients who do not have sickle cell disease or those who are not experiencing significant symptoms may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective and safer treatment option for patients with sickle cell disease, improving their quality of life and potentially extending their life expectancy.
How similar studies have performed: While there have been advancements in sickle cell disease treatments, this specific approach using sulfated non-anticoagulant heparin nanoparticles is novel and has not been extensively tested in clinical settings.
Where this research is happening
Wynantskill, United States
- Vascular Vision Pharmaceuticals Company — Wynantskill, United States (Active)
Researchers
- Principal investigator: Korczak, Bozena — Vascular Vision Pharmaceuticals Company
- Study coordinator: Korczak, Bozena
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.